In addition, downregulation of anti-apoptotic BCL-XL in LNCaP and PC-3 prostate cancer cells increases sensitivity to multiple chemotherapeutic agents, whereas overexpression of BCL-XL is cytoprotective [52]. Here, BCL2L1 is linked to prostate carcinoma.